Preoperative Platelet to Lymphocyte Ratio Is Associated with Early Morbidity and Mortality after Coronary Artery Bypass Grafting
AbstractObjective: To investigate the association of platelet to lymphocyte ratio to mortality and morbidity after coronary artery bypass grafting operation.
Methods: We evaluated records of 916 patients who underwent coronary artery bypass grafting operation between January 2009 and May 2014 retrospectively. Patients were grouped as Group 1 (n = 604) if the platelet to lymphocyte ratio was above 142 and Group 2 (n = 312) if platelet to lymphocyte ratio was below 142.
Results: The number of patients who developed a neurologic event during the hospital stay and in the first postoperative month was 7 (1.2%) in Group 1 and 12 (3.8%) in Group 2 for which the difference was statistically significant (P = .007). Early term mortality occurred in 3 patients (0.5%) in Group 1 and in 10 patients (3.2%) in Group 2 for which the difference was statistically highly significant (P = .001). In univariate and multivariate regression analysis, the preoperative platelet to lymphocyte ratio was determined as an independent risk factor for occurrence of atrial fibrillation in the early postoperative period, reoperation for sternum dehiscence, occurrence of a neurologic event, prolonged stay in the hospital and mortality.
Conclusion: In this study, elevated levels of platelet to lymphocyte ratio were associated with mortality and morbidity after coronary artery bypass grafting operation.
Aghdaii N, Ferasatkish R, Mohammadzadeh Jouryabi A, Hamidi SH. 2014. Significance of preoperative total lymphocyte count as a prognostic criterion in adult cardiac surgery. Anesth Pain Med 4:e20331.
Azab B, Shah N, Akerman M, McGinn JT Jr. 2012. Value of platelet/lymphocyte ratio as a predictor of all-cause mortality after non-ST elevation myocardial infarction. J Thromb Thrombolysis 34:326-34.
Bagger JP, Zindrou D, Taylor KM. 2003. Leukocyte count: a risk factor for coronary artery bypass graft mortality. Am J Med 115:660-3.
Baetta R, Corsini A. 2010. Role of polymorphonuclear neutrophils in atherosclerosis: current state and future perspectives. Atherosclerosis 210:1-13.
Benites-Zapata VA, Hernandez AV, Nagarajan V, Cauthen CA, Starling RC, Tang WH. 2015. Usefulness of neutrophil-to-lymphocyte ratio in risk stratification of patients with advanced heart failure. Am J Cardiol 115:57-61.
Bhat T, Teli S, Rijal J, et al. 2013. Neutrophil to lymphocyte ratio and cardiovascular diseases: a review. Expert Rev Cardiovasc Ther 11:55-9.
Bhatti I, Peacock O, Lloyd G, Larvin M, Hall RI. 2010. Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg 200:197-203.
Caligiuri G, Liuzzo G, Biasucci LM, Maseri A. 1998. Immune system activation follows inflammation in unstable angina: pathogenetic implications. J Am Coll Cardiol 32:1295-304.
Davi G, Patrono C. 2007. Platelet activation and atherothrombosis. N Engl J Med 357:2482-94.
De Cocker J, Messaoudi N, Stockman BA, Bossaert LL, Rodrigus IE. 2011. Preoperative prediction of intensive care unit stay following cardiac surgery. Eur J Cardiothorac Surg 39:60-7.
Dernellis J, Panaretou M. 2006. Effects of C-reactive protein and the third and fourth components of complement (C3 and C4) on incidence of atrial fibrillation. Am J Cardiol 97:245-8.
Gary T, Pichler M, Belaj K, at al. 2013. Platelet-to-lymphocyte ratio: a novel marker for critical limb ischemia in peripheral arterial occlusive disease patients. PLoS One 8:e67688.
Gary T, Pichler M, Belaj K, et al. 2013. Neutrophil-to-lymphocyte ratio and its association with critical limb ischemia in PAOD patients. PLoS One 8:e56745.
Gibson PH, Croal BL, Cuthbertson BH, et al. 2007. Preoperative neutrophil-lymphocyte ratio and outcome from coronary artery bypass grafting. Am Heart J 154:995-1002.
Gibson PH, Cuthbertson BH, Croal BL, et al. 2010. Usefulness of neutrophil/lymphocyte ratio as predictor of new-onset atrial fibrillation after coronary artery bypass grafting. Am J Cardiol 105:186-91.
Hansson GK. 2005. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685-9.
Horne BD, Anderson JL, John JM, et al. 2005. Intermountain Heart Collaborative Study Group. Which white blood cell subtypes predict increased cardiovascular risk? J Am Coll Cardiol 45:1638-43.
Kaya MG. 2013. Editorial comment: Inflammation and coronary artery disease: as a new biomarker neutrophil/lymphocyte ratio. Arch Turk Soc Cardiol 41:191-2.
Kundi H, Balun A, Çiçekcioğlu H, et al. 2015. Association between platelet to lymphocyte ratio and saphenous vein graft disease in patients with stable angina pectoris. Anatol J Cardiol doi: 10.5152/akd.2015.6224.
Kwon HC, Kim SH, Oh SY, et al. 2012. Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Biomarkers 17:216-22.
Libby P, Ridker PM, Maseri A. 2002. Inflammation and atherosclerosis. Circulation 105:1135-43.
Libby P, Ridker PM, Hansson GK. 2009. Leducq transatlantic network on atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 54:2129-38.
Min JJ, Nam K, Kim TK, et al. 2014. Relationship between early postoperative C-reactive protein elevation and long-term postoperative major adverse cardiovascular and cerebral events in patients undergoing off-pump coronary artery bypass graft surgery: a retrospective study. Br J Anaesth 113:391-401.
Newall N, Grayson AD, Oo AY, at al. 2006. Preoperative white blood cell count is independently associated with higher perioperative cardiac enzyme release and increased 1-year mortality after coronary artery bypass grafting. Ann Thorac Surg 81:583-9.
Ommen SR, Gibbons RJ, Hodge DO, Thomson SP. 1997. Usefulness of the lymphocyte concentration as a prognostic marker in coronary artery disease. Am J Cardiol 79:812-4.
Oylumlu M, Yıldız A, Oylumlu M, et al. 2015. Platelet-to-lymphocyte ratio is a predictor of in-hospital mortality patients with acute coronary syndrome. Anadolu Kardiyol Derg 15:277-83.
Pinna Pintor P, Bobbio M, Colangelo S, Veglia F, Marras R, Diena M. 2003. Can Euroscore predict direct costs of cardiac surgery? Eur J Cardiothorac Surg 23:595-8.
Proctor MJ, Morrison DS, Talwar D, et al. 2011. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 47:2633-41.
Temiz A, Gazi E, Güngör Ö, et al. 2014. Platelet/lymphocyte ratio and risk of in-hospital mortality in patients with ST-elevated myocardial infarction. Med Sci Monit 20:660-5.
Thomson SP, McMahon LJ, Nugent CA. 1980. Endogenous cortisol: a regulator of the number of lymphocytes in peripheral blood. Clin Immunol Immunopathol 17:506-14.
Unal D, Eroglu C, Kurtul N, Oguz A, Tasdemir A. 2013. Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis? Asian Pac J Cancer Prev 14:5237-42.
Ünal EU, Durukan AB, Özen A, et al. 2013. Neutrophil/lymphocyte ratio as a mortality predictor following coronary artery bypass graft surgery. Turk Gogus Kalp Dama 21:588-93.
Wang D, Yang JX, Cao DY, et al. 2013. Preoperative neutrophil-
lymphocyte and platelet-lymphocyte ratios as independent predictors of cervical stromal involvement in surgically treated endometrioid adenocarcinoma. Onco Targets Ther 6:211-6.
Yayla Ç, Canpolat U, Akyel A, et al. 2015. Association between platelet to lymphocyte ratio and saphenous vein graft disease angiology. pii: 0003319715578258. [Epub ahead of print].
Yüksel M, Yıldız A, Oylumlu M, et al. 2014. The association between platelet/lymphocyte ratio and coronary artery disease severity. Anadolu Kardiyol Derg doi: 10.5152/akd.2014.5565. [Epub ahead of print].
Zouridakis EG, Garcia-Moll X, Kaski JC. 2000. Usefulness of the blood lymphocyte count in predicting recurrent instability and death in patients with unstable angina pectoris. Am J Cardiol 86:449-51.
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).